Kenya vs Uganda: Average cost of drugs for extensively drug-resistant tuberculosis
Kenya
1,800 constant 2022 US$
in 2024
Uganda
1,709 constant 2022 US$
in 2024
Kenya rank
29th
Uganda rank
30th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Kenya
- Uganda
How they compare
Kenya currently reports 1,800 constant 2022 US$ against 1,709 constant 2022 US$ in Uganda, a difference of 91 constant 2022 US$.
That makes Kenya's figure about 1.1 times Uganda's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Kenya ahead.
Kenya ranks 29th and Uganda ranks 30th of 56 countries.
Across the 2 decades both report, Kenya averaged higher in 1 and Uganda in 1.
Head to head by decade
| Decade | Kenya | Uganda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,500 constant 2022 US$ | 3,356 constant 2022 US$ | 1,144 constant 2022 US$ | Kenya |
| 2020s | 2,706 constant 2022 US$ | 3,247 constant 2022 US$ | 541 constant 2022 US$ | Uganda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Kenya or Uganda?
- Kenya, at 1,800 constant 2022 US$ against 1,709 constant 2022 US$ in Uganda as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Kenya and Uganda?
- 91 constant 2022 US$, with Kenya ahead.
- How many years of comparable data are there for Kenya and Uganda?
- 8 years are reported by both, from 2017 to 2024.
- How do Kenya and Uganda rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Kenya ranks 29th and Uganda ranks 30th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.